SLAMF7 and plasma cell myeloma: It is likely that enhanced activity in the model was due to increased NK cell activation through elotuzumab-mediated ADCC, which occurred via recruitment of effector NK cells into SLAMF7/CS1+ tumor xenografts and lenalidomide-mediated direct cytotoxic effects against myeloma cells.